Klaus Lindpaintner

Dr. Lindpaintner serves as a Scientific and Clinical Advisor to PrognomiQ. He was most recently Chief Medical and Scientific Officer at InterVenn Biosciences. Previously, he was Vice President and Global Head, Human Genetics & Computational Medicine at Pfizer. He has also served as Chief Scientific Officer at Thermo Fisher Scientific, and as Chief Scientific Officer at SDIX. Earlier in his career, he was Vice President, Roche Center for Medical Genomics & Roche Distinguished Scientist at Roche Pharmaceuticals, and Associate Professor, Harvard University. Dr. Lindpaintner received his M.D. from Leopold-Franzens Universität Innsbruck, and a Masters of Public Health (M.P.H.) from Harvard. He is board certified in internal medicine, cardiology, and clinical and molecular genetics.